Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort

Abstract

Antidepressant administration is associated with lower depressive symptom level in patients with schizophrenia and MDD. Paranoid delusions and alcohol misuse disorder should be specifically explored and treated in cases of non-remission under treatment. MetS may play a role in MDD onset and/or maintenance in patients with schizophrenia.Declaration of interestNone.

Rethinking Schizophrenia and Depression Comorbidity as One Psychiatric Disorder Entity: Evidence From Mouse Model

“…As suggested by Figure 4, treatment with fluoxetine or risperidone effectively relieves the typical symptoms of depression or schizophrenia, whereas the combined drug application cannot relieve the helplessness or anhedonia symptoms in the MK801 + CUMS model. Such observations in mouse models largely agree with clinical observations showing the minimal alleviation of depressive symptoms by antidepressant treatment in schizophrenia patients complicated with depressive disorders (Fond et al, 2018). This behavioral observation is further substantiated by the analysis of neuronal recordings showing that the impaired neuronal activity in the PFC cannot be relieved by the combined antipsychotic and antidepressant treatment.…”

Hypovitaminosis D is associated with depression and anxiety in schizophrenia: Results from the national FACE-SZ cohort.

“…Due to the cross-sectional retrospective design, no causal association may be drawn from the present findings and further clinical trials are also needed to determine if vitamin D supplementation in patients with hypovitaminosis D may definitely improve depression and anxiety. Treating depression in schizophrenia remain a challenge in the current state of the art (Guillaume Fond et al, 2018), and vitamin D may be suggested as a low-cost and high benefit/risk ratio add-on therapy in SZ patients with depressive and anxiety symptoms.…”

“…The screening for depression and anxiety in SZ is rarely carried out. One explanation is the debate of the existence of major depression and anxiety disorders as comorbidities of schizophrenia (Guillaume Fond et al, 2018). Some authors suggest that anxiety and depressive symptoms are part of psychotic symptomatology (as measured by the PANSS depressive factor that includes anxiety and depressive symptoms) (Wallwork et al, 2012).…”

“…However, major depression has been shown to be associated with lower quality of life independently of negative symptoms (Andrianarisoa et al, 2017). The other reason may be the perception of lack of effectiveness of antidepressants in SZ subjects, while a recent study has shown that antidepressants were associated with lower depressive symptoms in SZ subjects (Guillaume Fond et al, 2018). Some depressive symptoms are also associated with insight into illness and therefore not necessarily treated (Roux et al, 2018).…”

“…Psychiatrists may therefore be doubtful on its efficacy, as vitamin D as an extremely good tolerance. Moreover, vitamin D may still not be identified an agent with psychotropic effects, despite the existence of vitamin D receptors in the brain and the efficacy on peripheral inflammation (G. Fond et al, 2018). Vitamin D has been recently shown to maintain extracellular fluid serotonin concentrations in the brain, thereby offering an explanation for how vitamin D could influence the trajectory and development of neuropsychiatric disorders (G. Fond et al, 2018).…”